BPC 157 is a synthetic pentadecapeptide, a chain of 15 amino acids, that is studied in cell culture and rodent models for its reported influence on angiogenic signalling, tendon fibroblast behaviour and experimental tissue injury. It has no single confirmed receptor, and most of its literature comes from one research network, so the quality and provenance of the evidence matter as much as the biology. This article summarises the structure, the proposed mechanisms, the published research areas and the analytical and storage standards needed for reproducible work. It is written for laboratory researchers and gives no guidance on use in people.
What is BPC 157?
BPC 157 is classified as a synthetic peptide fragment derived from a larger protein described as “body protection compound”, reported in human gastric juice. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, usually written GEPPPGKPADDAGLV. The molecular formula is C62H98N16O22, and the molecular weight is approximately 1419 Da for the free peptide. The sequence carries a run of three consecutive prolines and two adjacent aspartates, features that influence its conformation, solubility and chemical stability.
The peptide originates from work by Predrag Sikiric and colleagues at the University of Zagreb in Croatia, who were investigating protective factors in the gastrointestinal tract during the 1990s. Since then the group has produced a very large number of papers, and reviewers have noted that the great majority of the published work on BPC-157 comes from this single network of authors. That is not evidence of error, but it does mean that independent replication is limited and that conclusions should be treated as provisional until other groups confirm them.
Two points of nomenclature are worth knowing. The compound is written variously as BPC-157, BPC 157 and PL 14736, and the last is an older development code. A salt variant, BPC-157 arginate, is also marketed for improved stability. It is a different material from the acetate form usually supplied, with a different molecular weight and counterion content, and results with one form cannot be assumed to apply to the other. The certificate of analysis should state which is supplied.
Regulatory context matters for any UK buyer. BPC-157 is not an authorised medicine in the United Kingdom, and it appears on the World Anti-Doping Agency prohibited list. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued warnings about unlicensed products marketed for human use. The material is relevant here only as a laboratory research reagent.
Mechanism of action
No single receptor has been conclusively identified for BPC-157, and this is the most important thing to understand about its mechanism. The literature describes a set of proposed pathways and not a classical ligand-receptor interaction, and several of them rest on observations from a small number of groups.
The first proposed pathway concerns angiogenic signalling. Reports describe changes in the expression and phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) and in downstream signalling through Akt and endothelial nitric oxide synthase in endothelial cells, which connects the peptide to the regulation of new vessel formation in experimental injury models. How the peptide produces these changes at a molecular level is not settled.
The second proposed pathway involves nitric oxide signalling. Several rodent studies describe effects of the peptide that were altered by nitric oxide synthase inhibitors or donors, which the authors interpreted as interaction with the nitric oxide system. Interpretation is difficult, because nitric oxide is involved in most vascular and inflammatory processes and non-specific interactions are hard to exclude.
The third involves growth hormone receptor expression and focal adhesion signalling in tendon fibroblasts. Work in cultured rat tendon fibroblasts reported increased expression of the growth hormone receptor and activation of the JAK2 pathway after exposure to the peptide, along with effects on migration and survival. These are in-vitro cellular readouts and should not be extended beyond that.
A fourth theme is modulation of other systems, including dopaminergic and serotonergic pathways, reported in rodent behavioural pharmacology. These are the least well replicated claims in the literature.
For laboratory design, the practical consequence is that controls are essential. Vehicle controls, scrambled-sequence peptides and orthogonal readouts help separate specific effects from artefacts. In cell-based work, “dosage” means molar or microgram-per-millilitre concentration in the medium, which depends on net peptide content, adsorption to plasticware and protease activity in any serum used. Short peptides are degraded quickly by proteases, so stability in the medium should be checked.
What the research shows
The published literature on BPC 157 is large in volume and narrow in origin. Four areas are summarised below in general terms. Readers should consult the primary papers for methods, concentrations and statistics, because commercial summaries often overstate findings.
The first area is the original gastrointestinal work. Sikiric and colleagues published a long series of papers from the 1990s onwards describing the peptide in rat models of experimental gastric, intestinal and other mucosal lesions, with administration by injection, local application or in drinking water. These experiments were carried out in rats under ethical approval, and they are described here only as part of the scientific record. The early literature can be explored through a PubMed search on BPC 157 and gastric lesions in rats.
The second area is tendon biology. A group in Taiwan led by Chang and colleagues published work in the Journal of Applied Physiology in 2011 on a rat Achilles tendon model and on cultured tendon fibroblasts. They reported that, in culture, the peptide increased outgrowth from tendon explants, cell survival under stress and migration in a transwell assay. This is notable because it is among the few studies from outside the Zagreb network. A PubMed search for BPC 157 tendon fibroblast studies returns this work and a follow-up paper on growth hormone receptor expression.
The third area is angiogenesis and vascular signalling. Studies in endothelial cell culture have reported links between the peptide and VEGFR2 expression and signalling, and review articles from the originating group discuss the peptide alongside established angiogenic factors. These reviews draw heavily on the group’s own earlier work and are best read alongside independent critique.
The fourth area is the assessment of the evidence base as a whole. Systematic reviews of the musculoskeletal literature have concluded that the evidence is almost entirely preclinical, with very limited high-quality human data, and that the animal studies vary widely in design, route and reporting. This is a finding about the state of the field and not about the peptide’s biology.
A recurring limitation runs through the whole body of work. Routes, vehicles and exposures differ between papers, authorship is concentrated, and the exact material used is not always characterised analytically. Because of this, results cannot be compared across studies without examining the chemistry of the peptide that was actually used.
Research applications
In the laboratory, BPC 157 is used in several contexts, mostly preclinical. The most common is cell culture work on tendon fibroblasts, endothelial cells and other mesenchymal cell types, where it is a test compound in migration, survival and gene expression assays. Good practice is to run a concentration series with a scrambled-sequence control and to confirm peptide stability in the medium.
A second context is angiogenesis research. Tube-formation assays in endothelial cells, aortic ring assays and chorioallantoic membrane models have been used to examine how the peptide interacts with VEGF signalling, and researchers compare it with established angiogenic factors.
A third context is animal models of tissue injury, which require institutional ethical review and, in the United Kingdom, authorisation under the Animals (Scientific Procedures) Act 1986. Study design should include vehicle controls, blinded assessment and analytical confirmation of the material administered, because the history of the field shows how much conclusions depend on reproducibility.
A fourth context is analytical chemistry. BPC-157 is a useful model for developing liquid chromatography and mass spectrometry methods for proline-rich peptides, and reference material of defined identity and purity is used to develop detection methods for unlicensed peptide products, including in anti-doping research.
Purity, storage and handling
For a 15-residue peptide with three consecutive prolines, solid-phase synthesis can produce deletion sequences and truncated products, and proline-rich sequences can couple slowly. Reversed-phase high-performance liquid chromatography (HPLC) with UV detection at 214 or 220 nm is the standard purity method, and a main peak of at least 98 per cent is commonly expected for cell signalling work. The sequence contains no tryptophan or tyrosine, so absorbance at 280 nm is negligible and only the peptide bond region is informative. HPLC must be paired with mass spectrometry to confirm that the observed mass matches the theoretical value of about 1419 Da. A clean peak at the wrong mass is a clean peak of the wrong compound.
A batch-specific certificate of analysis matters because purity and peptide content vary between synthesis runs. It should carry a lot number matching the vial, the HPLC trace or purity value, the observed and theoretical masses, the test date and ideally the salt form and net peptide content. Lyophilised powders contain counterions and residual water, so the weighed mass is not the mass of peptide, and ignoring this introduces systematic errors into any concentration-response comparison. It also explains why a concentration quoted in a paper cannot be reproduced by weighing powder alone.
Because the aspartate-aspartate and aspartate-alanine motifs can isomerise or cleave once the peptide is in solution, batch-level verification matters more here than with more robust compounds. UK laboratories sourcing BPC 157 should expect a batch-specific certificate of analysis that states the salt form and the mass found, with lyophilised storage at -20°C, and the same documentation standard applies when weighing any best peptides supplier uk claim, since a supplier’s analytical record rather than its search ranking shows whether the vial matches its stated specification.
Lyophilised BPC-157 is generally stored at -20°C in a sealed container with desiccant, and many laboratories use -80°C for long-term archives. Vials should reach room temperature before opening so that condensation does not form on the cold powder. After reconstitution, stability falls. Standard practice is to dissolve the peptide in sterile water or a suitable buffer, divide the solution into single-use aliquots and freeze them to avoid repeated freeze-thaw cycles. Refrigerated storage at 2 to 8°C is sometimes used for solutions consumed within days, but the acceptable period should be validated for the assay concerned, preferably by re-running HPLC on stored solution. Neutral to alkaline pH can accelerate degradation at the aspartate residues.
Light sensitivity is a secondary concern, since the sequence has no tryptophan or tyrosine, but amber vials or dark storage remain good practice. Peptides also adsorb to glass and some plastics at low concentrations, so low-bind tubes are preferred for dilute working solutions.
Labelling is a final indicator of quality. Clear naming, sequence, molecular weight, lot number, salt form and an unambiguous research-only statement suggest a supplier that understands its market, while any wording that implies use in humans is a warning sign and raises regulatory concerns in the United Kingdom.
Frequently asked questions
What is BPC 157 used for in laboratory research?
It is used as a test compound in cell culture studies of tendon fibroblasts and endothelial cells, in angiogenesis assays and in approved animal injury models. It is a research reagent and not an authorised medicine in the United Kingdom.
Is there strong evidence for BPC-157?
The published evidence is almost entirely preclinical, and most of it comes from one research network. Independent replication is limited, and reviews describe high-quality human data as lacking. Findings from cell and rodent studies should be treated as provisional.
How should BPC 157 be stored for research?
Keep lyophilised peptide at -20°C, or -80°C for long-term archiving, in a sealed, dry, light-protected container. Allow vials to reach room temperature before opening. After reconstitution, aliquot and freeze the solution to avoid repeated freeze-thaw cycles.
How can I verify the purity of a BPC-157 batch?
Request a batch-specific certificate of analysis showing HPLC purity and a mass spectrometry result near 1419 Da, with the salt form and a lot number matching the vial. For critical work, independent testing by an accredited analytical laboratory confirms identity and purity.
BPC 157 is supplied for in-vitro laboratory research only and is not intended for human or veterinary use.
